In this podcast Dr Chiorean, director of the IBD Center for Excellence at Virginia Mason Medical Center in Seattle, Washington, reviews his presentation at the recent Advances in Inflammatory Bowel Diseases virtual meeting about the risks and reasons for de-escalating or stopping therapy for IBD.
In this podcast, Brian Lacy, MD, of the Mayo Clinic-Jacksonville, and Benjamin Lebwohl, MD, of Columbia University Medical Center in New York, discuss the prevalence of celiac disease, the importance--and challenges--of adhering to a gluten-free diet, the rise of gluten or wheat sensitivity, and more. This podcast is the first in a series.
In part 1 of a 5-part series on the challenges of treating perianal Crohn disease, Sara Horst, MD, and David Schwartz, MD, from Vanderbilt University Medical Center, discuss how to manage patient e
Dr Lacy, professor of medicine at Mayo Clinic Jacksonville, discusses the causes and treatment of abdominal distention and bloating.
In this podcast, Jonathan Stine, MD, from the the Milton S. Hershey Medical Center of Pennsylvania State University, discusses his proof-of-concept study on the effects of exercise on gut dysbiosis and fatty liver disease.
He discusses the American Journal of Gastroenterology's recent publication of a review of major advancements in gastroenterology over the previous decade.
In this podcast, Christina Y. Ha, MD, provides insight into the prevention and management of Clostridioides difficile infection among patients with inflammatory bowel disease. It is a topic she will be discussing at the upcoming virtual Advances in Inflammatory Bowel Diseases Regional Meeting.
He discusses research into the prevalence of gastroesophageal reflux disease and proton pump inhibitor-refractory GERD.
In this 12-minute podcast, Vrinda Bhardwaj, MD, from Children's Hospital Los Angeles, reviews the use of elemental and elimination diets for treatment of eosinophilic gastrointestinal diseases in children.
He discusses his session on endocrine pathways and therapeutic options for patients with nonalcoholic fatty liver disease, which he presented at Harvard University’s 21st Annual Symposium on NAFLD.